To look whether the investigational medication, Filgotinib, has an effect on spermatozoa in men with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.
For studying the efficacy and safety of Lonafarnib/Ritonavir with and without Pegylated Interferon -Alfa-2a. It is a Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy
The Synchronize 301 and Synchronize 303 research studies are looking at a non-antibiotic investigational drug targeted for use with two of the most common forms of pink eye – those caused by certain viruses (adenovirus) or bacterial infection.
The three studies aim to find out if an investigational study drug called Mirikizumab can cause and maintain remission in people with moderate to severe Ulcerative Colitis that haven’t responded to previous or current Ulcerative Colitis medicines.
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism.
- Efficacy and safety of the investigational medication Edoxaban in children and young people who have confirmed Venous Thromboembolism.
- Edoxaban versus Warfarin for the Treatment of Atrial Fibrillation.
Evaluation of Major Cardiovascular Events in Patients with, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo. The study will take place at approximately 1000 study centers in 30 countries. Approximately 12,600 adults with cardiovascular disease or who are at high risk for cardiovascular disease, have high cholesterol and have had complications related to taking statins, will take part in the study.
These are a pair of international clinical research studies looking at how effective and safe a new investigational medication is for treating people with chronic heart failure.
A. The EMPEROR-Preserved Study: This is for people with a type of heart failure called preserved ejection fraction. It is titled Empagliflozin outcome trial in patients With chronic heart failure with preserved ejection fraction.
B. The EMPEROR-Reduced Study: People who have a different type of heart failure called reduced ejection fraction will take part in Empagliflozin outcome trial in patients with chronic heart failure With reduced ejection fraction.
A phase III binary, parallel group, multi-sitecentric study to compare the performance and safety of Xluken v. Lucentis® among patients suffering from Neovascular age-related macular degeneration.